Molecular biology of natriuretic peptides and nitric oxide synthases

Cardiovascular Research

Volumn 51, Issue 3, 2001, Pages 429-441

  Kone, Bruce C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Endothelial factors; Endothelial function; G proteins; Natriuretic peptide; Nitric oxide; Signal transduction

Indexed keywords

ADENYLATE CYCLASE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALMODULIN; CYCLIC GMP; DENDROASPIS NATRIURETIC PEPTIDE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENE PRODUCT; GUANYLATE CYCLASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR 1; NATRIURETIC PEPTIDE RECEPTOR 2; NATRIURETIC PEPTIDE RECEPTOR 3; NATRIURETIC PEPTIDE TYPE C; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; PROTEIN G; PROTEIN SERINE THREONINE KINASE; RECEPTOR; UNCLASSIFIED DRUG; URODILATIN;

5' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; ARTERIAL PRESSURE; BINDING SITE; CELL FUNCTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE EXPRESSION; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA TRANSLATION;

ATRIAL NATRIURETIC FACTOR; GENE EXPRESSION REGULATION; HUMANS; NATRIURESIS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NITRIC OXIDE SYNTHASE; PEPTIDES; RECEPTORS, PEPTIDE;

EID: 0035882208     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00327-3     Document Type: Review

References (171)

1. A rapid and potent natruiretic response to intravenous injection of atrial myocardial extracts in rats
2. The Nobel chronicles. 1998: Robert Francis Furchgott (b 1911), Louis J Ignarro (b 1941), and Ferid Murad (b 1936)
3. Isolation and structural analysis of 'urodilatin', a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
4. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure
5. Renal actions of synthetic dendroaspis natriuretic peptide
6. Mechanism of relaxations to dendroaspis natriuretic peptide in canine coronary arteries
7. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps)
8. The sites of gene expression of atrial, brain, and C-type natriuretic peptides in mouse fetal development: Temporal changes in embryos and placenta
9. Atrial natriuretic factor messenger ribonucleic acid and peptide in the human heart during ontogenic development
10. Atrial natriuretic peptide and its messenger ribonucleic acid in overloaded and overload-released ventricles of rat
11. Renal and vascular effects of C-type and atrial natriuretic peptides in humans
12. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion
13. Suppression of plasma endothelin-1 level by alpha-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men
14. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide
15. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme
16. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension
17. Cloning of a cDNA encoding porcine brain natriuretic peptide
18. Human and canine gene homologs of porcine brain natriuretic peptide
19. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure
20. Cardiac fibrosis in mice lacking brain natriuretic peptide
21. C-type natriuretic peptide (CNP): A new member of natriuretic peptide family identified in porcine brain
22. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition
23. Effects of C-type natriuretic peptide on rat cardiac contractility
24. Effects of intravenously administered C-type natriuretic peptide in humans: Comparison with atrial natriuretic peptide
25. Molecular cloning and chromosomal assignment of the mouse C-type natriuretic peptide (CNP) gene (Nppc): Comparison with the human CNP gene (NPPC)
26. Gene and precursor structures of human C-type natriuretic peptide
27. Isolation and functional expression of the human atrial natriuretic peptide clearance receptor cDNA
28. Identification of the G protein-activating domain of the natriuretic peptide clearance receptor (NPR-C)
29. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system
30. Isolation and characterization of the 5′-flanking regulatory region of the human natriuretic peptide receptor C gene
31. i-2-dependent signaling by single-transmembrane natriuretic peptide clearance receptor
32. Hypertension associated with decreased testosterone levels in natriuretic peptide receptor-A gene-knockout and gene-duplicated mutant mouse models
33. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A
34. NPR-A-Deficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension
35. Phosphorylation of the kinase homology domain is essential for activation of the A-type natriuretic peptide receptor
36. Functional interaction of NF-Y and SP1 is required for type-A natriuretic peptide receptor gene transcription
37. Sp1 dependence of natriuretic peptide receptor A gene transcription in rat aortic smooth muscle cells
38. Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases
39. Identification and characterization of the major phosphorylation sites of the B-type natriuretic peptide receptor
40. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide
41. An E-box motif conveys inhibitory activity on the atrial natriuretic peptide gene
42. Context-dependent transcriptional cooperation mediated by cardiac transcription factors Csx/Nkx-2.5 and GATA-4
43. Up-regulation of natriuretic peptides in the ventricle of Csx/Nkx2-5 transgenic mice
44. p300 protein as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic factor gene
45. Involvement of multiple cis elements in basal- and alpha-adrenergic agonist-inducible atrial natriuretic factor transcription. Roles for serum response elements and an SP-1-like element
46. The Akt-glycogen synthase kinase 3β pathway regulates transcription of atrial natriuretic factor induced by β-adrenergic receptor stimulation in cardiac myocytes
47. Negative regulation of the human atrial natriuretic peptide gene by 1,25-dihydroxyvitamin D3
48. Hypoxia stimulates atrial natriuretic peptide gene expression in cultured atrial cardiocytes
49. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure
50. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
51. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction
52. Tissue-specific expression of the human brain natriuretic peptide gene in cardiac myocytes
53. Endothelin-dependent and -independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase
54. Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac
55. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes
56. Integrin dependence of brain natriuretic peptide gene promoter activation by mechanical strain
57. Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes
58. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro
59. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-β. Possible existence of 'vascular natriuretic peptide system'
60. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells - Evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells
61. Lipoproteins regulate C-type natriuretic peptide secretion from cultured vascular endothelial cells
62. Insulin suppresses endothelial secretion of C-type natriuretic peptide, a novel endothelium-derived relaxing peptide
63. Vascular endothelial growth factor suppresses C-type natriuretic peptide secretion
64. Four-kilobase sequence of the mouse CNP gene directs spatial and temporal expression of lacZ in transgenic mice
65. A novel transcriptional factor with Ser/Thr kinase activity involved in the transforming growth factor (TGF)-beta signalling pathway
66. Direct evidence of nitric oxide presence within mitochondria
67. Nitric oxide synthase activity in mitochondria
68. Lessons learned from nitric oxide synthase knockout animals
69. Altered immune responses in mice lacking inducible nitric oxide synthase
70. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase
71. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene
72. Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice
73. Attenuation of renal ischemia-reperfusion injury in inducible nitric oxide synthase knockout mice
74. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice
75. Hypertension in mice lacking the gene for endothelial nitric oxide synthase
76. Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase
77. The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia
78. Impaired wound healing and angiogenesis in eNOS-deficient mice
79. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene
80. Modulation of mouse cardiac function in vivo by eNOS and ANP
81. RNA diversity has profound effects on the translation of neuronal nitric oxide synthase
82. Structural organization of the human neuronal nitric oxide synthase gene (nNOS)
83. Expression of two types of nitric oxide synthase mRNA in human neuroblastoma cell lines
84. Cloning of a novel neuronal nitric oxide synthase expressed in penis and lower urinary tract
85. Neuronal nitric oxide synthase-μ, an alternatively spliced isoform expressed in differentiated skeletal muscle
86. Isolation and characterization of a novel, human neuronal nitric oxide synthase cDNA
87. Alternative splicing of human inducible nitric oxide synthase mRNA tissue specific regulation and induction by cytokines
88. Cloning and characterization of human inducible nitric oxide synthase splice variants: A domain, encoded by exons 8 and 9, is critical for dimerization
89. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese
90. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position 298
91. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK
92. Coronary artery disease is not associated with the E298→D variant of the constitutive, endothelial nitric oxide synthase gene
93. The glu298-asp (894G-T) mutation at exon 7 of the endothelial nitric oxide synthase gene and coronary artery disease
94. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia
95. Genetic risk factors for coronary artery spasm: Significance of endothelial nitric oxide synthase gene T-786→C and missense Glu298Asp variants
96. T-786→C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm
97. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T→C mutation associated with coronary spastic angina
98. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease
99. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene
100. Differential regulation of the two neuronal nitric-oxide synthase gene promoters by the Oct-2 transcription factor
101. The 5′2 promoter of the neuronal nitric oxide synthase dual promoter complex mediates inducibility by nerve growth factor
102. Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism
103. A novel, testis-specific mRNA transcript encoding an NH2-terminal truncated nitric-oxide synthase
104. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity
105. AMPK signaling in contracting human skeletal muscle: Acetyl-CoA carboxylase and NO synthase phosphorylation
106. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy
107. Interaction of nitric oxide synthase with the postsynaptic density protein psd 95 and alpha 1 syntrophin mediated by pdz domains
108. CAPON: A protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95
109. Interaction of neuronal nitric-oxide synthase with caveolin-3 in skeletal muscle. Identification of a novel caveolin scaffolding/inhibitory domain
110. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo
111. PIN: An associated protein inhibitor of neuronal nitric oxide synthase
112. Cloning and structure of a rabbit protein inhibitor of neuronal nitric oxide synthase (PIN) gene and its pseudogene
113. Neuronal nitric-oxide synthase is regulated by the Hsp90-based chaperone system in vivo
114. Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo
115. Macrophage nitric oxide synthase gene: Two upstream regions mediate induction by interferon gamma and lipopolysaccharide
116. Promoter of the mouse gene encoding calcium independent nitric oxide synthase confers inducibility by interferon-γ and bacterial lipopolysaccharide
117. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase
118. ESE-1 is a novel transcriptional mediator of inflammation that interacts with NF-κB to regulate the inducible nitric oxide synthase gene
119. A hypoxia responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter
120. A novel lipopolysaccharide-response element contributes to induction of nitric oxide synthase
121. CCAAT/enhancer binding protein-β trans-activates murine nitric oxide synthase-2 gene in an MTAL cell line
122. Role of interferon regulatory factor-1 in induction of nitric oxide synthase
123. Binding of the transcription factor interferon regulatory factor-1 to the inducible nitric-oxide synthase promoter
124. Both p38α(MAPK) and JNK/SAPK pathways are important for induction of nitric-oxide synthase by interleukin-1beta in rat glomerular mesangial cells
125. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene
126. Mitogen-activated protein kinases mediate AP-1-dependent human inducible nitric oxide synthase promoter activation
127. An inducible nitric-oxide synthase (NOS)-associated protein inhibits NOS dimerization and activity
128. Kalirin inhibition of inducible nitric-oxide synthase
129. NO synthase II in mouse skeletal muscle is associated with caveolin 3
130. Complex contribution of the 3′-untranslated region to the expressional regulation of the human inducible nitric-oxide synthase gene. Involvement of the RNA-binding protein HuR
131. Protein kinase C delta activation by IL-1β stabilises inducible NO synthase mRNA in pancreatic β-cells
132. β-Adrenergic stimulation of rat cardiac fibroblasts enhances induction of nitric-oxide synthase by interleukin-1 β via message stabilization
133. Modulation of inducible nitric oxide synthase mRNA stability by tetrahydrobiopterin in vascular smooth muscle cells
134. 2+ selectively suppresses IL-1-induced NO production by reducing iNOS mRNA stability
135. Autocrine regulation of inducible nitric-oxide synthase in macrophages by atrial natriuretic peptide
136. Tyrosine phosphorylation of inducible nitric oxide synthase: Implications for potential post-translational regulation
137. Estrogens increase transcription of the human endothelial NO synthase gene: Analysis of the transcription factors involved
138. Functional analysis of the human endothelial nitric oxide synthase promoter. Sp1 and GATA factors are necessary for basal transcription in endothelial cells
139. Transcriptional regulation of endothelial nitric-oxide synthase by lysophosphatidylcholine
140. Characterization of the human endothelial nitric-oxide synthase promoter
141. Transcriptional regulation of endothelial nitric-oxide synthase by an interaction between casein kinase 2 and protein phosphatase 2A
142. Characterization of an upstream enhancer region in the promoter of the human endothelial nitric oxide synthase gene
143. In vivo expression profile of an endothelial nitric oxide synthase promoter-reporter transgene
144. Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung
145. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure
146. Effects of shear on endothelial cell calcium in the presence and absence of ATP
147. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III)
148. Upregulation of endothelial nitric oxide synthase promoter by PI-3Kγ/Jak2/MEK-1-dependent pathway
149. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor beta 1
150. A vascular bed-specific pathway
151. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension
152. Evidence that an endothelial cytosolic protein binds to the 3′-untranslated region of endothelial nitric oxide synthase mRNA
153. Posttranscriptional regulation of endothelial nitric oxide synthase during cell growth
154. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide
155. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
156. Acylation targets endothelial nitric oxide synthase to plasmalemmal caveolae
157. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: Implications for caveolae localization
158. 2+-calmodulin and caveolin
159. The endothelial nitric-oxide synthase-caveolin regulatory cycle
160. Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1
161. Endothelial nitric oxide synthase interactions with G-protein-coupled receptors
162. Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase
163. AMP-activated protein kinase phosphorylation of endothelial NO synthase
164. Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases
165. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
166. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
167. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals
168. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
169. Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo
170. Calcium-independent activation of endothelial nitric oxide synthase by ceramide
171. Agonist-modulated targeting of the EDG-1 receptor to plasmalemmal caveolae. eNOS activation by sphingosine 1-phosphate and the role of caveolin-1 in sphingolipid signal transduction